ALDX - NASDAQ
Aldeyra Therapeutics, Inc.
$1.86
+0.71%Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
At a Glance
Live SnapshotAldeyra Therapeutics, Inc. Management Team
Dr. Stephen G. Machatha Ph.D.
Chief Development Officer
Compensation
$563,076
Dr. Todd C. Brady M.D., Ph.D.
Chief Executive Officer, President & Director
Compensation
$930,828
Mr. Michael Alfieri
Head of Finance and Principal Financial & Accounting Officer
Compensation
$111,650
David Burke
Head of Investor Relations
Laura Nichols
Operations Manager
Aldeyra Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $160K and sold $114K worth of ALDX shares, resulting in $46K of net buying activity.
3 Months
75.0K
105.10K
0
0.00
+105K
+$105K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
17.9K
54.71K
22.1K
113.71K
-59K
-$59K
Top Buyers
Douglas Richard
Director
$103K
Alfieri Michael
Officer: Principal Financial Officer
$20K
Phillips Gary M.
Director
$10K
Bronstein Ben
Director
$10K
Walker Neal
Director
$6K
Top Sellers
Machatha Stephen
Officer: Chief Development Officer
$114K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $46K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
SEC Filings
ALDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 27, 2026 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2024 | June 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 23, 2023 | June 30, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 14, 2021 | June 08, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | June 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 22, 2019 | June 04, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 25, 2018 | June 07, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 24, 2017 | June 08, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.